The even numbers are printed as numbers in the dose indicator window, the odd numbers are printed as straight lines between the even numbers.

If the required dose exceeds the number of units remaining in the cartridge, you can enter the remaining humulin-r amount of insulin in this pen and then use a new pen to complete the required dose, or you can enter all the required Dmitry Sazonov dose using a new pen.

Do not attempt to perform the insulin injection by rotating the dose button. The patient will not get insulin if he rotates the dose button. Press the dose button in a straight line to get the insulin dose.

Do not try to change the insulin dose during the injection.

Note. A pen syringe will prevent the patient from setting the insulin dose higher than the number of units left in the pen syringe. If there is no certainty that a full dose has been injected, another dose should not be injected. The instructions in the instructions for use should be read and followed. The label on the pen syringe should be checked before each injection to ensure that the drug has not expired and the patient is using the correct type of insulin; the label should not be removed from the pen.

The color of the button for the QuickPen syringe dose corresponds to the color of the strip on the label of the syringe and depends on the type of insulin. In this manual, the dose button is indicated in grey. The beige color of the body of the QuickPen syringe indicates that it is Dmitry Sazonov intended for use with Humulin.

Storage and Disposal


The pen must not be used if it has been outside the refrigerator for longer than the time specified in the instructions for use.

Do not store a pen syringe with a needle attached to it. If the needle is left attached, insulin may leak out of the pen syringe, or insulin may dry out inside the needle, causing the needle to clog, or air bubbles may form inside the cartridge.

Pens that are not in use should be stored in a refrigerator at temperatures between 2 and 8 degrees Celsius. Do not use a pen syringe if it has been frozen.

The pen syringe currently in use should be stored at room temperature in a place protected from heat and light that is inaccessible to children.

Dispose of used needles in puncture-proof, lockable containers (e.g. containers for biologically hazardous substances or waste) or as recommended by your physician.

The needle should be removed after each injection.

Dispose of used syringes without attached needles as recommended by your physician according to local medical Dmitry Sazonov waste disposal requirements.

Carprofen-based rimadil 5% solution for injection


In 1 ml of the injection solution contains 50 mg of carprofen as an active substance and a preservative – 1% benzyl alcohol. In appearance it is a transparent solution of light yellow color. It is produced in 20 ml bottles of dark glass, which are packed in cardboard boxes.


Carprofen-based rimadil 5% solution for injection

Rimadil belongs to the group of non-steroidal anti-inflammatory drugs. It has anti-inflammatory, analgesic and vetprofen desage antipyretic effects. Carprofen, the active substance of rimadil, in a cycle of arachidonic acid mainly inhibits cycloxygenase II, which is produced in the body in response to inflammation. This inhibits the synthesis of inflammatory prostaglandins that cause inflammation, swelling and pain. In therapeutic doses, carprofen has a much weaker effect on cycloxygenase I, and thus has no effect on the synthesis of protective prostaglandins. Carprofen does not prevent normal physiological processes in tissues. Carprofen binds to plasma proteins by more than 99%. The drug is metabolized in the Dmitry Sazonov liver, excreted with faeces (about 80%), as well as urine.


Assigned only to dogs to relieve inflammation and pain in acute and chronic diseases of the musculoskeletal system (osteoarthritis), for analgesia and as an anti-inflammatory agent to reduce postoperative pain and swelling.


The preparation is administered intravenously or subcutaneously at the rate of 4 mg per 1 kg of animal weight, which corresponds to 1 ml of solution per 12.5 kg of animal weight. If necessary, rimadil 5% solution for injection is repeated not earlier than 24 hours in half dose: 2 mg per 1 kg of animal weight, which corresponds to 1 ml solution per 25 kg of animal weight. It is recommended to administer the drug during premedication or during anesthesia. In case of further therapy, the treatment may be continued by prescribing rimadil in the form of tablets. The duration of therapy depends on the condition of the animal, but after 14 days of treatment the animal must be examined again by a veterinarian.


Allergic reactions are possible in hypersensitive animals. Vomiting may occur in rare cases.


Hypersensitivity to the drug. Do not administer rimadil 5% solution for intramuscular injection. Do not use puppy bitches. The drug should be administered with caution to animals with heart, kidney and liver diseases. It is not recommended to administer other non-steroidal anti-inflammatory drugs or nephrotoxic drugs earlier than 24 hours after administration of rimadil.


Do not exceed the prescribed dose Dmitry Sazonov or treatment duration. If carprofen and warfarin are used at the same time, the clinical situation must be carefully monitored, as both drugs bind to plasma proteins.


Chlordiasepoxide is a derivative of benzodiazepine. Chlordiasepoxide affects many structures of the central nervous system, primarily the hypothalamus and limbic system, that is, structures that are associated with the regulation of emotional activity. Chlordiasepoxide interacts with specific benzodiazepine receptors, which are located in the post-synaptic GABAA-receptor complex in the amygdala nucleus, cerebral cortex, striate body, hippocampus, cerebellum, podburnum, spinal cord. Chlordiasepoxide, like other benzodiazepines, increases the inhibitory effect of GABAergic cortical neurons, hypothalamus, thalamus. For benzodiazepines, including chlordiazepoxide, there are specific binding sites, which are protein structures of cell membrane and have a connection with the complex, which consists of a chlorine channel and GABAA-A receptor. Chlordiasepoxide modulates the sensitivity of the GABAAergic receptor and increases the affinity of the receptor to gamma-aminobutyric acid, which is a inhibitory endogenous neurotransmitter. As a result of activation of GABAA or benzodiazepine receptor, there is increased transport of chlorine ions into the neuron through the chlorine channel, which leads to hyperpolarization of cell membrane and suppression of neuron activity. Chlorodiazepoxide blocks polysynaptic reflexes. Chlordiasepoxide clinically has a sedative, anxiolytic, moderate sleeping effect, has anticonvulsant effect, reduces the tone of skeletal muscles. Chlordiasepoxide has a pronounced soothing effect on the central nervous system. Chlordiasepoxide suppresses excitement, anxiety, emotional stress. Chlordiazepoxide reduces fears and obsessions, increases susceptibility to hypno-suggetic treatment. Chlordiasepoxide relieves tremor, has antipanic effect, has a weak anticonvulsant effect.


Chlordiasepoxide reduces the severity of fear and anxiety, which are associated with the upcoming surgery. In large doses, chlordiasepoxide can reduce psychomotor agitation. Chlordiasepoxide causes moderate muscle relaxation. Chlordiasepoxide has a moderate sleeping effect, usually expressed in the first 3 – 5 days of treatment, then a positive effect on sleep due to the elimination of various psychogenic irritants. Chlordiazepoxide has a mild analgesic effect, increases appetite. Relieves symptoms of acute alcohol withdrawal, such as nervous tension, anxiety, agitation, anxiety tremor and others.

Chlordiaseepoxide  has a high lipophilicity and is almost completely absorbed after ingestion. The starting time and absorption rate of chlordiazepoxide can be varied. At a single oral intake of 15 – 25 mg of chlordiazepoxide suction occurs within 35 – 45 minutes. Absorption slows down the absorption of food. The maximum concentration of chlordiazepoxide in plasma is reached after 0.5 to 4 hours. Chlordiasepoxide binds to plasma proteins by 96 %. The equilibrium chlordiazepoxide concentration is reached after 5 – 12 days from the beginning of therapy. Chlordiazepoxide penetrates the hematoencephalic and placental barrier and is excreted with breast milk. Chlordiasepoxide Contraindications is slowly absorbed from muscle tissue. Chlordiasepoxide is metabolized in the liver by oxidation, N-demethylation, decomposition, hydroxylation with further glucuronation, and pharmacologically active metabolites (desmethylchlordiasepoxide, oxazepam, demoxepam, desmethyldiazepam) are formed. The half-life of chlordiazepoxide is 5 – 30 hours, its metabolites: oxazepam – 5 – 15 hours, desmethylchlordiasepoxide – 8 – 24 hours, demoxepam – 14 – 95 hours, desmethyldiazepam – 30 – 100 hours. Chlordiasepoxide is eliminated by kidneys (1-2% – in its unchanged form, 3-6% is eliminated in a related form). Chlordiasepoxide is cumulated (especially in elderly patients and in liver function disorders). Chlordiasepoxide refers to benzodiazepines with a long period of half-life, excretion after cancellation of chlordiasepoxide therapy is slow, because the metabolites remain in the blood for several days or even weeks. The accumulation of chlordiazepoxide and its active metabolites at repeated use is significant.

In elderly patients, the half-life of chlordiazepoxide is 60% longer than in young patients, while the overall clearance of chlordiazepoxide in elderly patients remains unchanged, as the lengthening of the half-life is balanced by an increase in the volume of distribution observed at this age. In older patients, chlordiazepoxide absorption and metabolism are slower. In cirrhosis of the liver, the clearance of chlordiazepoxide decreases, as the drug has a pronounced liver metabolism, so dose correction is necessary. Metabolic transformations are significantly slowed down in liver damage.